A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension
Authors:
- 6 March 2008
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 24 (4) , 1101-1114
Abstract
Objectives: The objective of this study was to evaluate the effects of losartan ± hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension.Research design and methods: Randomized patients (n = 261) were non-diabetic with systolic blood pressure (SBP) ≥ 140 and ≤ 180 mmHg and diastolic BP (DBP) ≥ 95 and ≤ 115 mmHg, body mass index > 30 kg/m2, and waist circumference > 40 (males)/> 35 (females) inches. Patients were randomized to placebo or a forced titration of losartan 50 mg titrated at 4-week intervals to losartan 100 mg, losartan 100 mg/HCTZ 12.5 mg, and losartan 100 mg/HCTZ 25 mg. Primary efficacy measurements were change from baseline in SBP and DBP at 12 weeks. Secondary measurements were change from baseline in BPs at 8 and 16 weeks, percent responders at 12 and 16 weeks, and safety/tolerability. Post-hoc analyses were BP at 4 weeks and achievement of controlled BP (SBP < 140 and/or DBP < 90 mmHg) at 12 and 16 weeks.Results: Losartan 50 mg reduced...Keywords
This publication has 38 references indexed in Scilit:
- Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial HypertensionHypertension, 2007
- Valsartan, Blood Pressure Reduction, and C-Reactive ProteinHypertension, 2006
- Weight Loss and the Renin-Angiotensin-Aldosterone SystemHypertension, 2005
- CorrectionHypertension, 2005
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004
- Angiotensin receptor antagonist losartan improves endothelial function of epicardial coronary arteries in patients with essential hypertensionClinical Cardiology, 2002
- Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartanBritish Journal of Pharmacology, 2001
- Primary Prevention of Ischemic StrokeStroke, 2001
- Body-Mass Index and Mortality in a Prospective Cohort of U.S. AdultsNew England Journal of Medicine, 1999
- The Effect of Weight Reduction on Blood Pressure, Plasma Renin Activity, and Plasma Aldosterone Levels in Obese PatientsNew England Journal of Medicine, 1981